Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (FMT) is an investigational microbial therapy being evaluated by the Shanghai Mental Health Center for the treatment of Anorexia Nervosa (AN). The therapy involves the oral administration of encapsulated fecal matter from healthy donors to patients with AN to restore gut microbial diversity and stability. The underlying mechanism is based on the gut-brain axis, where intestinal dysbiosis is thought to contribute to the psychological and physiological symptoms of eating disorders. By repopulating the gastrointestinal tract with commensal bacteria, FMT aims to improve nutritional status, facilitate weight gain, and alleviate psychiatric symptoms associated with AN. In clinical trials, the therapy is administered as a short-term intensive course of capsules to hospitalized patients, often in combination with conventional treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplantation (Shanghai Mental Health Center).